Dynavax deal

DVAX out-licensed its immunostimulatory sequence (ISS)-based cancer, HBV and HCV therapeutics to Symphony Dynamo. The cancer product is in an ongoing Phase II trial for non-Hodgkin's lymphoma (NHL), w...